🟢 Tscan Therapeutics is trading 5% up in pre-market with no clear catalyst identified

Tscan Therapeutics is trading at $0.23, up 5.17% in pre-market on October 14, 2026, with no clear company-specific catalyst identified.

• Tscan Therapeutics’ investor-relations press-release listing shows its latest release was dated October 6.
• The Cellares manufacturing collaboration appearing in search results was announced earlier, not today.
• The supplied major-index moves were modest and mixed, offering no clear broader-market explanation.